135 related articles for article (PubMed ID: 24785301)
1. Efficacious inhaled PDE4 inhibitors with low emetic potential and long duration of action for the treatment of COPD.
De Savi C; Cox RJ; Warner DJ; Cook AR; Dickinson MR; McDonough A; Morrill LC; Parker B; Andrews G; Young SS; Gilmour PS; Riley R; Dearman MS
J Med Chem; 2014 Jun; 57(11):4661-76. PubMed ID: 24785301
[TBL] [Abstract][Full Text] [Related]
2. GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species.
Rutter AR; Poffe A; Cavallini P; Davis TG; Schneck J; Negri M; Vicentini E; Montanari D; Arban R; Gray FA; Davies CH; Wren PB
J Pharmacol Exp Ther; 2014 Jul; 350(1):153-63. PubMed ID: 24784567
[TBL] [Abstract][Full Text] [Related]
3. In vivo characterization of GSK256066, a high-affinity inhaled phosphodiesterase 4 inhibitor.
Nials AT; Tralau-Stewart CJ; Gascoigne MH; Ball DI; Ranshaw LE; Knowles RG
J Pharmacol Exp Ther; 2011 Apr; 337(1):137-44. PubMed ID: 21205924
[TBL] [Abstract][Full Text] [Related]
4. The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity.
Davis TG; Peterson JJ; Kou JP; Capper-Spudich EA; Ball D; Nials AT; Wiseman J; Solanke YE; Lucas FS; Williamson RA; Ferrari L; Wren P; Knowles RG; Barnette MS; Podolin PL
J Pharmacol Exp Ther; 2009 Sep; 330(3):922-31. PubMed ID: 19498103
[TBL] [Abstract][Full Text] [Related]
5. Effects of the new benzimidazole derivative TAS-203, an orally active phosphodiesterase 4 inhibitor, on airway inflammation in rats and emetic responses in ferrets.
Asaka N; Kakuo H; Ohmori K; Sasaki E; Togawa M; Yamada S; Oka T; Kiniwa M
Arzneimittelforschung; 2010; 60(9):564-70. PubMed ID: 21117500
[TBL] [Abstract][Full Text] [Related]
6. The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses.
Vanmierlo T; Creemers P; Akkerman S; van Duinen M; Sambeth A; De Vry J; Uz T; Blokland A; Prickaerts J
Behav Brain Res; 2016 Apr; 303():26-33. PubMed ID: 26794595
[TBL] [Abstract][Full Text] [Related]
7. Anti-neutrophilic inflammatory activity of ASP3258, a novel phosphodiesterase type 4 inhibitor.
Kubo S; Kobayashi M; Iwata M; Miyata K; Takahashi K; Shimizu Y
Int Immunopharmacol; 2012 Jan; 12(1):59-63. PubMed ID: 22041526
[TBL] [Abstract][Full Text] [Related]
8. [Roflumilast: clinical review of a new option for the treatment of inflammation in COPD].
Martínez FJ
Arch Bronconeumol; 2010 Nov; 46 Suppl 9():8-11. PubMed ID: 21320811
[No Abstract] [Full Text] [Related]
9. Roflumilast for the treatment of chronic obstructive pulmonary disease.
Rabe KF
Expert Rev Respir Med; 2010 Oct; 4(5):543-55. PubMed ID: 20649375
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic evaluation of roflumilast.
Lahu G; Nassr N; Hünnemeyer A
Expert Opin Drug Metab Toxicol; 2011 Dec; 7(12):1577-91. PubMed ID: 22059647
[TBL] [Abstract][Full Text] [Related]
11. PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast.
Boswell-Smith V; Spina D
Int J Chron Obstruct Pulmon Dis; 2007; 2(2):121-9. PubMed ID: 18044684
[TBL] [Abstract][Full Text] [Related]
12. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
13. In vivo efficacy in airway disease models of N-(3,5-dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), a selective phosphodiesterase 4 inhibitor for inhaled administration.
Kuss H; Hoefgen N; Johanssen S; Kronbach T; Rundfeldt C
J Pharmacol Exp Ther; 2003 Oct; 307(1):373-85. PubMed ID: 12944497
[TBL] [Abstract][Full Text] [Related]
14. Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late phase airflow obstruction in Brown Norway rats.
Chapman RW; House A; Jones H; Richard J; Celly C; Prelusky D; Ting P; Hunter JC; Lamca J; Phillips JE
Eur J Pharmacol; 2007 Oct; 571(2-3):215-21. PubMed ID: 17610865
[TBL] [Abstract][Full Text] [Related]
15. Combined inhibition of PDE4 and PI3Kδ modulates the inflammatory component involved in the progression of chronic obstructive pulmonary disease.
Dinavahi SS; Nyayapathy S; Perumal Y; Dharmarajan S; Viswanadha S
Drug Res (Stuttg); 2014 Apr; 64(4):214-9. PubMed ID: 24105104
[TBL] [Abstract][Full Text] [Related]
16. Phosphodiesterase inhibitors in the treatment of inflammatory diseases.
Page CP; Spina D
Handb Exp Pharmacol; 2011; (204):391-414. PubMed ID: 21695650
[TBL] [Abstract][Full Text] [Related]
17. The in vitro pharmacology of GS-5759, a novel bifunctional phosphodiesterase 4 inhibitor and long acting β2-adrenoceptor agonist.
Tannheimer SL; Sorensen EA; Cui ZH; Kim M; Patel L; Baker WR; Phillips GB; Wright CD; Salmon M
J Pharmacol Exp Ther; 2014 Apr; 349(1):85-93. PubMed ID: 24513870
[TBL] [Abstract][Full Text] [Related]
18. Identification of 2,3-disubstituted pyridines as potent, non-emetic PDE4 inhibitors.
Kawasaki M; Fusano A; Nigo T; Nakamura S; Ito MN; Teranishi Y; Matsumoto S; Toda H; Nomura N; Sumiyoshi T
Bioorg Med Chem Lett; 2014 Jun; 24(12):2689-92. PubMed ID: 24794103
[TBL] [Abstract][Full Text] [Related]
19. CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration.
Moretto N; Caruso P; Bosco R; Marchini G; Pastore F; Armani E; Amari G; Rizzi A; Ghidini E; De Fanti R; Capaldi C; Carzaniga L; Hirsch E; Buccellati C; Sala A; Carnini C; Patacchini R; Delcanale M; Civelli M; Villetti G; Facchinetti F
J Pharmacol Exp Ther; 2015 Mar; 352(3):559-67. PubMed ID: 25576075
[TBL] [Abstract][Full Text] [Related]
20. Discovery and Optimization of 4-(8-(3-Fluorophenyl)-1,7-naphthyridin-6-yl)transcyclohexanecarboxylic Acid, an Improved PDE4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease (COPD).
Press NJ; Taylor RJ; Fullerton JD; Tranter P; McCarthy C; Keller TH; Arnold N; Beer D; Brown L; Cheung R; Christie J; Denholm A; Haberthuer S; Hatto JD; Keenan M; Mercer MK; Oakman H; Sahri H; Tuffnell AR; Tweed M; Trifilieff A
J Med Chem; 2015 Sep; 58(17):6747-52. PubMed ID: 26288344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
